Yohei Matsui

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Satomi Tanaka, Junji Uchino, Takashi Yokoi et al. · Diagnostics · 2022 · 36 citations · Full text

Medicine, Immunology, Oncology +17

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura et al. · npj Precision Oncology · 2023 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer

Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda et al. · Cancer Letters · 2024 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

Pathogenicity of Mycolicibacterium phlei, a non-pathogenic nontuberculous mycobacterium in an immunocompetent host carrying anti-interferon gamma autoantibodies: a case report

Satomi Tanaka, Yoshihiko Hoshino, Takuro Sakagami et al. · BMC Infectious Diseases · 2019 · 17 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab

Ryo Sawada, Yohei Matsui, Junji Uchino et al. · Internal Medicine · 2021 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17